OBJECTIVE To assess pair-wise differences between placebo, estrogen, and each of three estrogen-progestin regimens on selected symptoms. METHODS This was a 3-year, multicenter, double-blind, placebo-controlled trial in 875 postmenopausal women aged 45-64 years at baseline. Participants were assigned randomly to one of five groups: 1) placebo, 2) daily conjugated equine estrogens, 3) conjugate...

BACKGROUND The effect of combined hormone therapy on breast cancer detection is not established. METHODS We examined the effect of combined hormone therapy on breast cancer detection in the Women's Health Initiative trial, which randomized 16,608 postmenopausal women to receive conjugated equine estrogens (0.625 mg/d) plus medroxyprogesterone acetate (2.5 mg/d) or placebo. Mammography and bre...

A 39-year-old woman was admitted to our hospital with symptoms of general fatigue, nausea, and vomiting that appeared three months after she stopped seven years of medroxyprogesterone acetate (MPA) medication for endometrial stromal sarcoma. Laboratory tests demonstrated moderate hypercalcemia. Several tests demonstrated that she was suffering from adrenal insufficiency. Glucocorticoid suppleme...

The 2002 National Survey of Family Growth reported that 5.3% of all US women aged 15 through 44 currently using contraception used DMPA.1 Among contraceptors, 13.9% of those aged 15 to 19 and 10.1% of those aged 20 to 24 currently used DMPA compared with 1.6% of those aged 40 to 44.1 Decreasing rates of adolescent pregnancy between 1995 and 2002 are considered to be due in part to increased use...

This report reviews some of the new studies regarding new hormonal contraceptive formulations (e.g., Yaz, Qlaira(®), extended-cycle or continuous combined contraceptives, subcutaneous depot medroxyprogesterone acetate, and ulipristal acetate as an emergency contraceptive). Recent data on the relationship between hormonal contraceptive use and bone health are also reviewed.

Medroxyprogesterone Acetate To the Editor: I have read the article by Wakatsuki et al1 with considerable interest. The study showed that the continuous oral treatment of postmenopausal women for 3 months with conjugated equine estrogens (CEE) (0.625 mg/day) alone or with medroxyprogesterone acetate (MPA) at the dose of 2.5 mg/day, significantly increased serum C-reactive protein (CRP) and amylo...

Objective To determine the concentration changes of medroxyprogesterone acetate (MPA) in serum and milk in the Chinese lactating women who used Depo Geston® Methods Ten postpartum and breastfeeding women received an injectable contraceptive of Depo Geston® (depo medroxyprogesterone acetate,DMPA, 150 mg/ampoule). Serum and milk samples were collected in the 1st, 2nd, 4th, 6th, 8th 10th and 12th ...